The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating web-based and Internet-based applications/interventions, including mobile interventions, electronic games (incl multiplayer games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 - description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be
a) a guide for reporting for authors of RCTs,
b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a., 4b etc are original CONSORT or CONSORT-NPT (non-pharmacologic treatment) items.
Items with Roman numerals (i., ii, iii, iv etc.) are CONSORT-EHEALTH extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red *.
In the textboxes, either copy & paste the relevant sections from your manuscript into this form - please include any quotes from your manuscript in QUOTATION MARKS, or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED).
Please fill in these questions diligently. Information will not be copyedited, so please use proper spelling and grammar, use correct capitalization, and avoid abbreviations.

DO NOT FORGET TO SAVE AS PDF _AND_ CLICK THE SUBMIT BUTTON SO YOUR ANSWERS ARE IN OUR DATABASE !!!

Citation Suggestion (if you append the pdf as Appendix we suggest to cite this paper in the caption):
Eysenbach G, CONSORT-EHEALTH Group
CONSORT-EHEALTH: Improving and Standardizing Evaluation Reports of Web-based and Mobile Health Interventions
J Med Internet Res 2011;13(4):e126
doi: 10.2196/jmir.1923
PMID: 22209829

* Required

Your name *
First Last
Martin Cernvall
Primary Affiliation (short), City, Country *
University of Toronto, Toronto, Canada
Uppsala University, Uppsala,

Your e-mail address *
abc@gmail.com
martin.cernvall@pubcare.uu.se

Title of your manuscript *
Provide the (draft) title of your manuscript.

Twelve-month follow-up of a randomized controlled trial of internet-based guided self-help for parents of children on cancer treatment

Article Preparation Status/Stage *
At which stage in your article preparation are you currently (at the time you fill in this form)
- not submitted yet - in early draft status
- not submitted yet - in late draft status, just before submission
- submitted to a journal but not reviewed yet
- submitted to a journal and after receiving initial reviewer comments
- submitted to a journal and accepted, but not published yet
- published
- Other:

Journal *
If you already know where you will submit this paper (or if it is already submitted), please provide the journal name (if it is not JMIR, provide the journal name under "other")
- not submitted yet / unclear where I will submit this
- Journal of Medical Internet Research (JMIR)
- Other:

Manuscript tracking number *
If this is a JMIR submission, please provide the manuscript tracking number under "other" (The ms tracking number can be found in the submission acknowledgement email, or when you login as author in JMIR. If the paper is already published in JMIR, then the ms tracking number is the four-digit number at the end of the DOI, to be found at the bottom of each published article in JMIR)
- no ms number (yet) / not (yet) submitted to / published in JMIR
- Other:

TITLE AND ABSTRACT

1a) TITLE: Identification as a randomized trial in the title

1a) Does your paper address CONSORT item 1a? *
I.e does the title contain the phrase “Randomized Controlled Trial”? (if not, explain the reason under "other")

- yes
- Other: 

1a-i) Identify the mode of delivery in the title
Identify the mode of delivery. Preferably use “web-based” and/or “mobile” and/or “electronic game” in the title. Avoid ambiguous terms like “online”, “virtual”, “interactive”. Use “Internet-based” only if Intervention includes non-web-based Internet components (e.g. email), use “computer-based” or “electronic” only if offline products are used. Use “virtual” only in the context of “virtual reality” (3-D worlds). Use “online” only in the context of “online support groups”. Complement or substitute product names with broader terms for the class of products (such as “mobile” or “smart phone” instead of “iphone”), especially if the application runs on different platforms.

1 2 3 4 5

subitem not at all important ○ ○ ○ ○ essential

Does your paper address subitem 1a-i? *
Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Title: "Twelve-month follow-up of a randomized controlled trial of internet-based guided self-help for parents of children on cancer treatment"

1a-ii) Non-web-based components or important co-interventions in title
Mention non-web-based components or important co-interventions in title, if any (e.g., “with telephone support”).

1 2 3 4 5

subitem not at all important ○ ○ ○ ○ essential

Does your paper address subitem 1a-ii?
Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We have no relevant non-web-based components or important co-interventions.

1a-iii) Primary condition or target group in the title
Mention primary condition or target group in the title, if any (e.g., “for children with Type I Diabetes”) Example: A Web-based and Mobile Intervention with Telephone Support for Children with Type I Diabetes: Randomized Controlled Trial

1 2 3 4 5
1b) ABSTRACT: Structured summary of trial design, methods, results, and conclusions

NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.

1b-i) Key features/functionalities/components of the intervention and comparator in the METHODS section of the ABSTRACT

Mention key features/functionalities/components of the intervention and comparator in the abstract. If possible, also mention theories and principles used for designing the site. Keep in mind the needs of systematic reviewers and indexers by including important synonyms. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

From abstract: "This study was a parallel randomized controlled trial comparing a 10-week internet-based guided self-help program including weekly support from a therapist via encrypted e-mail to a wait-list control condition. The intervention was based on cognitive behavior therapy and focused on psychoeducation and skills to cope with difficult thoughts and feelings."

1b-ii) Level of human involvement in the METHODS section of the ABSTRACT

Clarify the level of human involvement in the abstract, e.g., use phrases like "fully automated" vs. "therapist/nurse/care provider/physician-assisted" (mention number and expertise of providers involved, if any). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)
Does your paper address subitem 1b-ii?
Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

From abstract: "This study was a parallel randomized controlled trial comparing a 10-week internet-based guided self-help program including weekly support from a therapist via encrypted e-mail to a wait-list control condition. The intervention was based on cognitive behavior therapy and focused on psychoeducation and skills to cope with difficult thoughts and feelings."

1b-iii) Open vs. closed, web-based (self-assessment) vs. face-to-face assessments in the METHODS section of the ABSTRACT

Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic or a closed online user group (closed usergroup trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment). Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials). Note: In traditional offline trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered. To avoid confusion, use "blinded" or "unblinded" to indicated the level of blinding instead of "open", as "open" in web-based trials usually refers to "open access" (i.e. participants can self-enrol). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

1 2 3 4 5

subitem not at all important ○ ○ ○ ○ essential

Does your paper address subitem 1b-iii?
Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

From abstract: "Parents of children on cancer treatment meeting the modified symptom criteria on the PTSD-Checklist, were invited by healthcare personnel at pediatric oncology centers and provided self-report assessments online."

1b-iv) RESULTS section in abstract must contain use data
Report number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

1 2 3 4 5

subitem not at all important ○ ○ ○ ○ essential

Does your paper address subitem 1b-iv?
Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.
From abstract: "Fifty-eight parents of children on cancer treatment (median months since diagnosis = three) were included in the study (intervention n = 31, and control n = 27). Eighteen participants completed the intervention. Sixteen participants in each group participated in the 12-month follow-up."

1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials
Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome - if the trial is negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

Our primary outcome had positive findings, however there were some negative (no change) in secondary outcomes. This is addressed in the abstract: "Future research should corroborate these findings and also develop and evaluate interventions and policies that may help ameliorate the economic burden that parents may face during their child’s treatment for cancer."

INTRODUCTION

2a) In INTRODUCTION: Scientific background and explanation of rationale

2a-i) Problem and the type of system/solution
Describe the problem and the type of system/solution that is object of the study: intended as stand-alone intervention vs. incorporated in broader health care program? Intended for a particular patient population? Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions? (Note: Details about the intervention are provided in “Methods” under 5)
"As the medical treatment for pediatric cancer is highly specialized, families where a child is treated for cancer often live far from the center where the child receives its care. This distance can make it difficult to maintain proper psychosocial and psychological support. Research have reported that less than half of parents who report a need to see a psychologist have had the opportunity to do so [12]. Cognitive behavior therapy provided via the internet is a promising treatment modality for a range of conditions [13] including parents of children with traumatic brain injury [14]. Providing interventions via the internet could potentially increase access of support for parents of children who are receiving treatment for cancer."

2a-ii) Scientific background, rationale: What is known about the (type of) system
Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropriate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.

1 2 3 4 5

subitem not at all important ☐ ☐ ☐ ☐ ☐ essential

Does your paper address subitem 2a-ii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"As the medical treatment for pediatric cancer is highly specialized, families where a child is treated for cancer often live far from the center where the child receives its care. This distance can make it difficult to maintain proper psychosocial and psychological support. Research have reported that less than half of parents who report a need to see a psychologist have had the opportunity to do so [12]. Cognitive behavior therapy provided via the internet is a promising treatment modality for a range of conditions [13] including parents of children with traumatic brain injury [14]. Providing interventions via the internet could potentially increase access of support for parents of children who are receiving treatment for cancer."

2b) In INTRODUCTION: Specific objectives or hypotheses

Does your paper address CONSORT subitem 2b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The purpose of the current study is to investigate the efficacy of the intervention including data from the controlled follow-up 12 months after randomization."
3a) Description of trial design (such as parallel, factorial) including allocation ratio

Does your paper address CONSORT subitem 3a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"This is a parallel randomized controlled trial including pre- and post-assessments, and a controlled follow-up 12 months after randomization, comparing an internet-based guided self-help program with a wait-list control condition."

3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons

Does your paper address CONSORT subitem 3b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Potential participants were approached by a nurse or physician at the pediatric oncology centers four to twelve weeks after the child’s diagnosis. In the initial protocol potential participants were to be approached 1-2 weeks after diagnosis. However, during the first months of inclusion it was evident that this was not feasible and parents often were approached later, and the protocol was changed to the time frame reported."

3b-i) Bug fixes, Downtimes, Content Changes

Bug fixes, Downtimes, Content Changes: ehealth systems are often dynamic systems. A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) (5-iii) and other "unexpected events" that may have influenced study design such as staff changes, system failures/downtimes, etc. [2].

1 2 3 4 5

subitem not at all important  0  0  0  0  essential

Does your paper address subitem 3b-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We had no such events.
4a) Eligibility criteria for participants

Does your paper address CONSORT subitem 4a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"In brief, eligible participants were parents of children on treatment for a cancer disease who were fluent in Swedish, had access to a computer with an internet connection, and fulfilled the modified symptom criteria on the PTSD-Checklist Civilian Version (PCL-C) [17], a self-report instrument corresponding to the DSM-IV criteria for PTSD [18], and did not suffer from any other psychiatric disorder in immediate need of treatment. The modified symptom criteria comprise scoring >3 on at least 1 of 5 symptoms of re-experiencing, 1 of 7 symptoms of avoidance, and 1 of 5 symptoms of hyper-arousal, corresponding to partial PTSD [19]."

4a-i) Computer / Internet literacy
Computer / Internet literacy is often an implicit “de facto” eligibility criterion - this should be explicitly clarified.

Does your paper address subitem 4a-i? 
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"had access to a computer with an internet connection"

4a-ii) Open vs. closed, web-based vs. face-to-face assessments:
Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree got the study team to know the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple identities was possible or whether technical or logistical measures (e.g., cookies, email confirmation, phone calls) were used to detect/prevent these.

Does your paper address subitem 4a-ii? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study
"Potential participants were approached by a nurse or physician at the pediatric oncology centers four to twelve weeks after the child’s diagnosis."

"Potential participants were provided written and oral information about the study and were asked for written consent to participate. A psychologist from the research group contacted consenting parents via telephone and parents were instructed to complete the screening/pre-assessment online. Thereafter a clinical interview with a psychologist was conducted via telephone."

4a-iii) Information giving during recruitment
Information given during recruitment. Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.

1 2 3 4 5

subitem not at all important ○ ○ ○ ○ essential

Does your paper address subitem 4a-iii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Potential participants were provided written and oral information about the study and were asked for written consent to participate."

4b) Settings and locations where the data were collected

Does your paper address CONSORT subitem 4b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Parents were instructed to complete the screening/pre-assessment online. Thereafter a clinical interview with a psychologist was conducted via telephone."
In the ms the reader can derive from the context that participants could complete the online assessment and telephone interview from a location that suited them.

4b-i) Report if outcomes were (self-)assessed through online questionnaires
Clearly report if outcomes were (self-)assessed through online questionnaires (as common in web-based trials) or otherwise.

1 2 3 4 5

subitem not at all important ○ ○ ○ ○ essential
Does your paper address subitem 4b-i? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"parents were instructed to complete the screening/pre-assessment online."

4b-ii) Report how institutional affiliations are displayed
Report how institutional affiliations are displayed to potential participants [on ehealth media], as affiliations with prestigious hospitals or universities may affect volunteer rates, use, and reactions with regards to an intervention. (Not a required item – describe only if this may bias results)

1 2 3 4 5

subitem not at all important ○ ○ ○ ○ essential

Does your paper address subitem 4b-ii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Not relevant for this ms as it is not thought to influence the rate or aspects of inclusion.

5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered

5-i) Mention names, credential, affiliations of the developers, sponsors, and owners
Mention names, credential, affiliations of the developers, sponsors, and owners [6] (if authors/evaluators are owners or developer of the software, this needs to be declared in a “Conflict of interest” section or mentioned elsewhere in the manuscript).

1 2 3 4 5

subitem not at all important ○ ○ ○ ○ essential

Does your paper address subitem 5-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.
"The authors were responsible for the development of the intervention being investigated."

5-ii) Describe the history/development process
Describe the history/development process of the application and previous formative evaluations (e.g., focus groups, usability testing), as these will have an impact on adoption/use rates and help with interpreting results.

1 2 3 4 5

subitem not at all important ◯ ◯ ◯ ◯ essential

Does your paper address subitem 5-ii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The material has been described in detail [15] as well as its use in the current trial [16]."

In the ms we refer to prior publications describing the development of the intervention in more detail.

5-iii) Revisions and updating
Revisions and updating. Clearly mention the date and/or version number of the application/intervention (and comparator, if applicable) evaluated, or describe whether the intervention underwent major changes during the evaluation process, or whether the development and/or content was "frozen" during the trial. Describe dynamic components such as news feeds or changing content which may have an impact on the replicability of the intervention (for unexpected events see item 3b).

1 2 3 4 5

subitem not at all important ◯ ◯ ◯ ◯ essential

Does your paper address subitem 5-iii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The intervention or software to provide it was not update or changed during the trial. This is implicated in the text.

5-iv) Quality assurance methods
Provide information on quality assurance methods to ensure accuracy and quality of information provided [1], if applicable.
Does your paper address subitem 5-iv?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Not applicable. The software used to provide the self-help intervention had been used extensively in research before.

5-v) Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used.
Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used. Replicability (i.e., other researchers should in principle be able to replicate the study) is a hallmark of scientific reporting.

Does your paper address subitem 5-v?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Not applicable.

5-vi) Digital preservation
Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, webcitation.org, and/or publishing the source code or screenshots/videos alongside the article). As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.

Does your paper address subitem 5-vi?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.
5-vii) Access
Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group. If known, describe how participants obtained “access to the platform and Internet” [1]. To ensure access for editors/reviewers/readers, consider to provide a “backdoor” login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).

subitem not at all important 1 2 3 4 5 essential

Does your paper address subitem 5-vii? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Potential participants were approached by a nurse or physician at the pediatric oncology centers four to twelve weeks after the child’s diagnosis. In the initial protocol potential participants were to be approached 1-2 weeks after diagnosis. However, during the first months of inclusion it was evident that this was not feasible and parents often were approached later, and the protocol was changed to the time frame reported. Potential participants were provided written and oral information about the study and were asked for written consent to participate. A psychologist from the research group contacted consenting parents via telephone and parents were instructed to complete the screening/pre-assessment online. Thereafter a clinical interview with a psychologist was conducted via telephone. Three master's level psychologists conducted the interviews. Participants in the intervention condition completed the post-assessment online immediately after the intervention. Participants in the wait-list control condition completed the post-assessment online after the corresponding time (i.e., 10-weeks post randomization). Participants in both conditions completed the follow-up online 12 months after randomization. Thereafter, participants in the wait-list condition were offered access to the intervention.”

We believe that the reader can derive from the ms that this was a study conducted in a clinical context, targeting a specific group, and that there were no costs associated with participation.

5-viii) Mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework
Describe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who developed it) [1], whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback” [6]. This also includes a description of communication delivery channels and – if computer-mediated communication is a component – whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].

subitem not at all important 1 2 3 4 5 essential
Does your paper address subitem 5-viii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The material has been described in detail [15] as well as its use in the current trial [16]. It consists of approximately 100 pages (A4 format) of text and visual material presented in nine modules. The intervention is based on cognitive behavior therapy (CBT) principles [20–22] and focuses on psycho-education and teaching strategies to manage the current situation of being a parent of a child on cancer treatment and the stressors it entails. Components include relaxation training, coping with distressing thoughts and feelings, behavioral experiments, problem-solving, structured emotional writing, values and goal setting, general self-care, and maintenance of behavior change."

"Participants accessed the intervention material via an online portal and were instructed to work with each module for one week. Each participant was assigned a therapist, and was instructed to send completed homework assignments via the portal to the therapist once each week. The therapist provided written feedback on each assignment and general progress through the intervention via the portal. The sequence of modules was fixed which enhanced treatment integrity."

5-ix) Describe use parameters

Describe use parameters (e.g., intended “doses” and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum.

1 2 3 4 5

subitem not at all important ○ ○ ○ ○ essential

Does your paper address subitem 5-ix?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"During the recruitment phase and in the informed consent participants had been informed that the intervention would imply about four hours of work per week."

5-x) Clarify the level of human involvement

Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as “type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered”. It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

1 2 3 4 5

subitem not at all important ○ ○ ○ ○ essential
Does your paper address subitem 5-x?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"Each participant was assigned a therapist, and was instructed to send completed homework assignments via the portal to the therapist once each week. The therapist provided written feedback on each assignment and general progress through the intervention via the portal. The sequence of modules was fixed which enhanced treatment integrity. If participants had not submitted their homework they were sent an e-mail reminder to log in to the system. During the recruitment phase and in the informed consent participants had been informed that the intervention would imply about four hours of work per week.

There were three therapists in the study. One licensed psychologist and two psychologists with a master’s degree in psychology. The two non-licensed psychologists received supervision from the licensed psychologist. The therapists were affiliated with the research group responsible for the study and independent from centers from which participants were recruited. Logging of therapist time and activities was not supported by the portal but therapists were instructed to spend 15-20 minutes per week when providing feedback to each participant."

5-xi) Report any prompts/reminders used

Report any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to use the application, what triggered them, frequency etc. It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

Does your paper address subitem 5-xi? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"If participants had not submitted their homework they were sent an e-mail reminder to log in to the system."

5-xii) Describe any co-interventions (incl. training/support)

Describe any co-interventions (incl. training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as eHealth intervention may not be designed as stand-alone intervention. This includes training sessions and support [1]. It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

Does your paper address subitem 5-xii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.
All participants were free to receive psychosocial services from the regular healthcare. These may have differed between centers as there are no standardized psychosocial services for parents within the Swedish pediatric oncology care setting.

6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed

Does your paper address CONSORT subitem 6a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"PTSS was the primary outcome and secondary outcomes included symptoms of depression, anxiety, and health-economic outcomes such as health-care consumption and sick-leave."

"A psychologist from the research group contacted consenting parents via telephone and parents were instructed to complete the screening/post-assessment online. Thereafter a clinical interview with a psychologist was conducted via telephone. Three master's level psychologists conducted the interviews. Participants in the intervention condition completed the post-assessment online immediately after the intervention. Participants in the wait-list control condition completed the post-assessment online after the corresponding time (i.e., 10-weeks post randomization). Participants in both conditions completed the follow-up online 12 months after randomization. Thereafter, participants in the wait-list condition were offered access to the intervention."

6a-i) Online questionnaires: describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed

If outcomes were obtained through online questionnaires, describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed [9].

1 2 3 4 5

subitem not at all important ◁ ◁ ◁ ◁ essential

Does your paper address subitem 6a-i?
Copy and paste relevant sections from manuscript text

We are unaware of a formal validation for online use of the primary outcome PTSD - Checklist.

6a-ii) Describe whether and how “use” (including intensity of use/dosage) was defined/measured/monitored
Describe whether and how “use” (including intensity of use/dosage) was defined/measured/monitored (logins, logfile analysis, etc.). Use/adoption metrics are important process outcomes that should be reported in any ehealth trial.

Does your paper address subitem 6a-ii?

"As reported previously [16], adherence to the intervention was operationalized as the numbers of treatment modules accessed and logins to the online portal. In the intervention group, six participants did not start the intervention and seven discontinued before completion. A total of 18 participants were considered as completers, representing 58% of those allocated to the intervention."

6a-iii) Describe whether, how, and when qualitative feedback from participants was obtained

Describe whether, how, and when qualitative feedback from participants was obtained (e.g., through emails, feedback forms, interviews, focus groups).

Does your paper address subitem 6a-iii?

This was obtained as part of the online post-assessment after the intervention, but is not reported in this ms.

6b) Any changes to trial outcomes after the trial commenced, with reasons

Does your paper address CONSORT subitem 6b? *

There were no changes in the trial outcomes.

7a) How sample size was determined
NPT: When applicable, details of whether and how the clustering by care provides or centers was addressed

7a-i) Describe whether and how expected attrition was taken into account when calculating the sample size
Describe whether and how expected attrition was taken into account when calculating the sample size.

1 2 3 4 5

subitem not at all important ☐ ☐ ☐ ☐ essential

Does your paper address subitem 7a-i?
Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"[19]. A power analysis indicated that a total of 72 participants needed to be included, with a power of 0.80, detect a large effect size (d = 0.80) on the PCL-C assuming p < .05. Given that data on health-care visits and sick-leave were collected and that such variables generally vary more than clinical efficacy, a sample of 120 participants was estimated appropriate. However, the participation rate during the four years of inclusion was considerably lower than expected and due to administrative reasons inclusion had to be terminated before this sample size was reached."

7b) When applicable, explanation of any interim analyses and stopping guidelines

Does your paper address CONSORT subitem 7b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We had no interim analyses or stopping rules.

8a) Method used to generate the random allocation sequence
NPT: When applicable, how care providers were allocated to each trial group

Does your paper address CONSORT subitem 8a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study
Randomization was performed by a consultant independent from the research group. Proc Plan SAS version 9.1 was used to generate the randomization schedule and sealed envelopes were prepared by the consultant and handed to the research group. Parents were randomized in 1:1 ratio to intervention or wait-list and the randomization was stratified according to center, parental gender, and whether a participant had a partner in the study or not. Partners were randomized to the same condition.

8b) Type of randomisation; details of any restriction (such as blocking and block size)

Does your paper address CONSORT subitem 8b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Randomization was performed by a consultant independent from the research group. Proc Plan SAS version 9.1 was used to generate the randomization schedule and sealed envelopes were prepared by the consultant and handed to the research group. Parents were randomized in 1:1 ratio to intervention or wait-list and the randomization was stratified according to center, parental gender, and whether a participant had a partner in the study or not. Partners were randomized to the same condition."

9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

Does your paper address CONSORT subitem 9? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Randomization was performed by a consultant independent from the research group. Proc Plan SAS version 9.1 was used to generate the randomization schedule and sealed envelopes were prepared by the consultant and handed to the research group. Parents were randomized in 1:1 ratio to intervention or wait-list and the randomization was stratified according to center, parental gender, and whether a participant had a partner in the study or not. Partners were randomized to the same condition."

10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions

Does your paper address CONSORT subitem 10? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study
Randomization was performed by a consultant independent from the research group. Proc Plan SAS version 9.1 was used to generate the randomization schedule and sealed envelopes were prepared by the consultant and handed to the research group. Parents were randomized in 1:1 ratio to intervention or wait-list and the randomization was stratified according to center, parental gender, and whether a participant had a partner in the study or not. Partners were randomized to the same condition.

11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how

NPT: Whether or not administering co-interventions were blinded to group assignment

11a-i) Specify who was blinded, and who wasn't

Specify who was blinded, and who wasn't. Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering co-interventions (if any).

<table>
<thead>
<tr>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>subitem not at all important</td>
<td></td>
<td></td>
<td></td>
<td>essential</td>
</tr>
</tbody>
</table>

Does your paper address subitem 11a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Neither participants nor therapists in the study were blind to condition allocation. This study relied on self-reported outcomes."

11a-ii) Discuss e.g., whether participants knew which intervention was the “intervention of interest” and which one was the “comparator”

Informed consent procedures (4a-ii) can create biases and certain expectations - discuss e.g., whether participants knew which intervention was the “intervention of interest” and which one was the “comparator”.

<table>
<thead>
<tr>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>subitem not at all important</td>
<td></td>
<td></td>
<td></td>
<td>essential</td>
</tr>
</tbody>
</table>

Does your paper address subitem 11a-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study
11b) If relevant, description of the similarity of interventions

(this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to an active medication/intervention)

Does your paper address CONSORT subitem 11b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not relevant as comparison was intervention vs. wait-list.

12a) Statistical methods used to compare groups for primary and secondary outcomes

NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed

Does your paper address CONSORT subitem 12a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study
Independent samples T-test, Mann Whitney U-test, χ²-test, and Fisher exact test were used to test for between-group differences on demographic characteristics and outcomes at pre-assessment. For the continuous outcomes (PCL-C, BDI-II, BAI) mixed effects modelling with full maximum likelihood estimation was used to examine potential change across assessments and effects of the intervention [28] including random intercepts and slopes. Analyses were conducted on the intention-to-treat (ITT) principle where all randomized participants are included in the analyses assuming missing data to be missing at random [29]. Condition was dummy coded with intervention = 1, control = 0. Assessment (pre, post, 12-month follow-up) was included as a continuous time-variable coded: pre = 0, post = 1, follow-up = 2. Models were tested stepwise with increasing complexity and selected based on model fit indices, i.e., Akaike Information Criteria (AIC) and Bayesian Information Criteria (BIC). The data missing mechanism was assessed prior to the main analyses by exploring the relationships between characteristics at pre-assessment and missing data. Standardized effect sizes (Cohen’s d) between groups at post-assessment and 12-month follow-up were calculated using the model estimated mean differences (by recoding the continuous time-variable to –1 0 1 to set the intercept at the post-assessment, and -2 -1 0 to set the intercept at the 12-month follow-up assessment), and standard deviations from pre-assessment [30]. The magnitude of the effect expressed in d was interpreted according to Cohen [31], i.e., 0.2 = small, 0.5 = medium, and 0.8 = large. Variables pertaining to economic data were categorical. However, ITT analyses with these data using e.g., generalized estimating equations, were not feasible due to the small sample size and results for this secondary outcome are based on the available data excluding participants with missing data. Between-group differences at pre-, post- and follow-up assessments were analyzed with χ²-tests or Fisher’s Exact Test. Due to the small sample size clustering by center and child was not addressed in any of the analyses. Analyses were performed in IBM SPSS Statistics 22.

12a-i) Imputation techniques to deal with attrition / missing values

Imputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in ehealth trials. Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic [4]).

<table>
<thead>
<tr>
<th>subitem not at all important</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>essential</th>
</tr>
</thead>
</table>

Does your paper address subitem 12a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study
"For the continuous outcomes (PCL-C, BDI-II, BAI) mixed effects modelling with full maximum likelihood estimation was used to examine potential change across assessments and effects of the intervention [28] including random intercepts and slopes. Analyses were conducted on the intention-to-treat (ITT) principle where all randomized participants are included in the analyses assuming missing data to be missing at random [29]. 
"Variables pertaining to economic data were categorical. However, ITT analyses with these data using e.g., generalized estimating equations, were not feasible due to the small sample size and results for this secondary outcome are based on the available data excluding participants with missing data."

12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses

Does your paper address CONSORT subitem 12b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We did no subgroup analyses or adjusted analyses.

X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item)

X26-i) Comment on ethics committee approval

1 2 3 4 5

subitem not at all important ☐ ☐ ☐ ☐ essential

Does your paper address subitem X26-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The procedure was approved by the regional ethics review board in Uppsala (Dnr 2008/238) and all participants provided written informed consent."

x26-ii) Outline informed consent procedures
Outline informed consent procedures e.g., if consent was obtained offline or online (how? Checkbox, etc.?), and what information was provided (see 4a-ii). See [6] for some items to be included in informed consent
documents.

Does your paper address subitem X26-ii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Potential participants were approached by a nurse or physician at the pediatric oncology centers four to twelve weeks after the child’s diagnosis".
"Potential participants were provided written and oral information about the study and were asked for written consent to participate."

X26-iii) Safety and security procedures
Safety and security procedures, incl. privacy considerations, and any steps taken to reduce the likelihood or detection of harm (e.g., education and training, availability of a hotline)

Does your paper address subitem X26-iii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not described in the ms, but there were telephone checkups after each online assessment and indications of deterioration was probed during these telephone check-up.

RESULTS

13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome

NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center

Does your paper address CONSORT subitem 13a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study
Fifty-eight parents of 46 children were included and randomized. Baseline characteristics have been described previously [16] and observed characteristics are presented in Table 1. There were no differences in baseline characteristics between groups except for the BAI with a higher score in the intervention group. The last follow-up assessment took place in August 2015.

Fourteen participants in the intervention group (45%) and seven in the wait-list group (26%) did not provide post-assessments. Furthermore, one participant in the intervention group and four in the wait-list group did not provide follow-up assessments, resulting in 16 participants in each group at 12-month follow-up.

13b) For each group, losses and exclusions after randomisation, together with reasons

Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown in a CONSORT flow diagram) *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

See CONSORT DIAGRAM in figure 1.

13b-i) Attrition diagram

Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or using the intervention/comparator in each group plotted over time, similar to a survival curve) or other figures or tables demonstrating usage/dose/engagement.

1 2 3 4 5

subitem not at all important ○ ○ ○ ○ essential

Does your paper address subitem 13b-i?

Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We have not included such a diagram and we believe that this information is included in the CONSORT diagram.

14a) Dates defining the periods of recruitment and follow-up
Does your paper address CONSORT subitem 14a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Between April 2010 and May 2014, 747 potential participants were informed about the study and asked for consent to be contacted again of which 553 declined."
"The last follow-up assessment took place in August 2015."

14a-i) Indicate if critical "secular events" fell into the study period
Indicate if critical "secular events" fell into the study period, e.g., significant changes in Internet resources available or "changes in computer hardware or Internet delivery resources"

1 2 3 4 5

subitem not at all important ◯ ◯ ◯ ◯ ◯ essential

Does your paper address subitem 14a-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No such events.

14b) Why the trial ended or was stopped (early)

Does your paper address CONSORT subitem 14b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The trial was not stopped earlier than expected but we included less participants than expected.
"However, the participation rate during the four years of inclusion was considerably lower than expected and due to administrative reasons inclusion had to be terminated before this sample size was reached."

15) A table showing baseline demographic and clinical characteristics for each group

NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group

Does your paper address CONSORT subitem 15? *
15-i) Report demographics associated with digital divide issues
In ehealth trials it is particularly important to report demographics associated with digital divide issues, such as age, education, gender, social-economic status, computer/Internet/ehealth literacy of the participants, if known.

Does your paper address subitem 15-i? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Age, education, gender is reported in Table 1. We did not assess computer/Internet literacy.

16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups

16-i) Report multiple “denominators” and provide definitions
Report multiple “denominators” and provide definitions: Report N's (and effect sizes) “across a range of study participation [and use] thresholds” [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants “used” the intervention/comparator at specific pre-defined time points of interest (in absolute and relative numbers per group). Always clearly define “use” of the intervention.

Does your paper address subitem 16-i? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study
In the results presented in table 2 and 3 the denominator for each analysis is presented.

16-ii) Primary analysis should be intent-to-treat
Primary analysis should be intent-to-treat, secondary analyses could include comparing only “users”, with the appropriate caveats that this is no longer a randomized sample (see 18-i).

Does your paper address subitem 16-ii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"For the continuous outcomes (PCL-C, BDI-II, BAI) mixed effects modelling with full maximum likelihood estimation was used to examine potential change across assessments and effects of the intervention [28] including random intercepts and slopes. Analyses were conducted on the intention-to-treat (ITT) principle where all randomized participants are included in the analyses assuming missing data to be missing at random [29]."

17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)

Does your paper address CONSORT subitem 17a?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, see table 2.

17a-i) Presentation of process outcomes such as metrics of use and intensity of use
In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational definitions is critical. This does not only refer to metrics of attrition (13-b) (often a binary variable), but also to more continuous exposure metrics such as “average session length”. These must be accompanied by a technical description how a metric like a “session” is defined (e.g., timeout after idle time) [1] (report under item 6a).
Does your paper address subitem 17a-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

due to the small sample size we could not analyses process aspects of the study, such as dose-response relationships.

17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended

Does your paper address CONSORT subitem 17b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes, see table 3.

18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory

Does your paper address CONSORT subitem 18? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

No subgroup or adjusted analyses.

18-i) Subgroup analysis of comparing only users
A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii).
Does your paper address subitem 18-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No such analyses for the primary outcomes.

19) All important harms or unintended effects in each group
(for specific guidance see CONSORT for harms)

Does your paper address CONSORT subitem 19? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

In the CONSORT diagram we have included reasons for exclusion and attrition due to adverse events (i.e., child’s death and severe depression).

19-i) Include privacy breaches, technical problems
Include privacy breaches, technical problems. This does not only include physical "harm" to participants, but also incidents such as perceived or real privacy breaches [1], technical problems, and other unexpected/unintended incidents. "Unintended effects" also includes unintended positive effects [2].

1 2 3 4 5

subitem not at all important ○ ○ ○ ○ essential

Does your paper address subitem 19-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We did experience such events.

19-ii) Include qualitative feedback from participants or observations from staff/researchers
Include qualitative feedback from participants or observations from staff/researchers, if available, on strengths and shortcomings of the application, especially if they point to unintended/unexpected effects or uses. This includes (if available) reasons for why people did or did not use the application as intended by the developers.
DISCUSSION

22) Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence

NPT: In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group

22-i) Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use)

Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use).

"The results indicate that the intervention was effective in terms of reductions in PTSS, depression, and anxiety and those improvements were maintained or strengthened, at the 12-month follow-up. However, there was no support for the intervention being effective in reducing healthcare consumption or sick-leave."

22-ii) Highlight unanswered new questions, suggest future research

Highlight unanswered new questions, suggest future research.
Does your paper address subitem 20-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"Future research should aim to disentangle whether psychological distress contributes to strains on household economy among parents of children on cancer treatment. Such efforts should be able to better prepare research that aims to alleviate the economic burden imposed on parents on children with cancer, be it via psychosocial interventions or targeted policies."

"Future trials should include active control conditions that allow for the control of the non-specific factors (e.g., attention, information and social support) that psychological interventions may be associated with.

"Historically, fathers have been less involved in pediatric psychology research [32] and future research with parents of children with cancer should take steps to ensure involvement from parents of both sexes [33]."

"Future research should corroborate these findings and also develop and evaluate interventions and policies that may help ameliorate the economic burden that parents may face during their child’s treatment for cancer."

---

**20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses**

**20-i) Typical limitations in ehealth trials**

Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trials often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.

```
1 2 3 4 5
```

- subitem not at all important
- essential

Does your paper address subitem 20-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.
"It may also be the case that we used a less than optimal instrument for assessing health-related consumption and sick-leave. Future research is needed to develop reliable and valid instruments for assessing these factors in the current population and such research could preferably start with qualitative methods in order to explore the phenomena health-related costs in this population." "However, using an inactive control group makes it impossible to draw conclusions regarding the specificity of the intervention. Future trials should include active control conditions that allow for the control of the non-specific factors (e.g., attention, information and social support) that psychological interventions may be associated with. Furthermore, the sample was small and attrition was substantial which may limit the validity of the ITT-analyses, and may hamper the generalizability of the findings. In addition, fathers were less likely to participate at the 12-month follow-up than mothers, which may further limit the generalizability. Unfortunately, the small sample size made it difficult to further explore the underlying mechanism of this difference in attrition. Historically, fathers have been less involved in pediatric psychology research [32] and future research with parents of children with cancer should take steps to ensure involvement from parents of both sexes [33]. Finally, this study relied on self-reported outcomes and participants were not blind to their study condition which should be kept in mind when interpreting findings."

21) Generalisability (external validity, applicability) of the trial findings

NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial

21-i) Generalizability to other populations

Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations

| Subitem not at all important | 1 | 2 | 3 | 4 | 5 | Essential |

Does your paper address subitem 21-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Furthermore, the sample was small and attrition was substantial which may limit the validity of the ITT-analyses, and may hamper the generalizability of the findings. In addition, fathers were less likely to participate at the 12-month follow-up than mothers, which may further limit the generalizability." "Using the internet to provide psychological interventions may be an effective mode of delivery for parents reporting an increased level of PTSS and who consider internet-based interventions as a viable option."

21-ii) Discuss if there were elements in the RCT that would be different in a routine application setting

Discuss if there were elements in the RCT that would be different in a routine application setting (e.g., prompts/reminders, more human involvement, training sessions or other co-interventions) and what impact
the omission of these elements could have on use, adoption, or outcomes if the intervention is applied outside of a RCT setting.

<table>
<thead>
<tr>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>subitem not at all important</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>

Does your paper address subitem 21-ii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We have adressed this in our ms. We feel that it would be important to corroborate these findings in future trials before implementation of this intervention into routine care. This is also explicitly stated in the conclusions:
"Future research should corroborate these findings and also develop and evaluate interventions and policies that may help ameliorate the economic burden that parents may face during their child’s treatment for cancer."

OTHER INFORMATION

23) Registration number and name of trial registry

Does your paper address CONSORT subitem 23? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This trial was not registered. This is clearly stated in the ms:
" During the planning of this study, trial registration was less common in the field of psychology than it is currently. Therefore this trial was not registered in a WHO accredited trial registry."

24) Where the full trial protocol can be accessed, if available

Does your paper address CONSORT subitem 24? *
Cite a Multimedia Appendix, other reference, or copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We have not published the trial protocol anywhere.
25) Sources of funding and other support (such as supply of drugs), role of funders

**Does your paper address CONSORT subitem 25?**

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"Funding
This research was supported by grants from the Swedish Research Council (grant numbers K2008-70X-20836-01-3 and K2011-70X-20836-04-4), the Swedish Cancer Society (grant number 2010/276), and the Swedish Childhood Cancer Foundation (grant numbers 2010/276), and the Swedish Childhood Cancer Foundation (grant numbers PROJ08/010 and PRO12/028)."

X27) Conflicts of Interest (not a CONSORT item)

**X27-i) State the relation of the study team towards the system being evaluated**

In addition to the usual declaration of interests (financial or otherwise), also state the relation of the study team towards the system being evaluated, i.e., state if the authors/evaluators are distinct from or identical with the developers/sponsors of the intervention.

<table>
<thead>
<tr>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>subitem not at all important</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Does your paper address subitem X27-i?**

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"Conflict of interest
The authors declare no conflicts of interest. The authors were responsible for the development of the intervention being investigated."

About the CONSORT EHEALTH checklist

**As a result of using this checklist, did you make changes in your manuscript?**

- yes, major changes
- yes, minor changes
- no

**What were the most important changes you made as a result of using this checklist?**
Clarifying non-blinding in the study and some limitations of the study.

How much time did you spend on going through the checklist INCLUDING making changes in your manuscript *
3-4 hours

As a result of using this checklist, do you think your manuscript has improved? *
☐ yes
☐ no
☐ Other:

Would you like to become involved in the CONSORT EHEALTH group?
This would involve for example becoming involved in participating in a workshop and writing an "Explanation and Elaboration" document
☐ yes
☐ no
☐ Other:

Any other comments or questions on CONSORT EHEALTH
No.

STOP - Save this form as PDF before you click submit
To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a Mac, simply select "print" and then select "print as PDF") before you submit it.

When you submit your (revised) paper to JMIR, please upload the PDF as supplementary file.

Don't worry if some text in the textboxes is cut off, as we still have the complete information in our database. Thank you!

Final step: Click submit!
Click submit so we have your answers in our database!

Submit

Never submit passwords through Google Forms.